TMEM91: A Potential Drug Target and Biomarker for Membrane Transport and Trafficking in Chronic Pain

Target Name: TMEM91

NCBI ID: G641649

TMEM91

TMEM91: A Potential Drug Target and Biomarker for Membrane Transport and Trafficking in Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain, along with its debilitating effects on quality of life, can lead to significant morbidity and mortality. The underlying mechanisms of chronic pain are complex and involve various signaling pathways, including the regulation of ion channels and transmembrane proteins.TMEM91, a transmembrane protein (TMEM), is a promising drug target and biomarker for understanding the molecular mechanisms of chronic pain. In this article, we will discuss the molecular mechanisms of TMEM91, its potential as a drug target, and its potential as a biomarker for the diagnosis and treatment of chronic pain.

Molecular Mechanisms of TMEM91

TMEM91 is a 22-kDa protein that is expressed in various tissues, including brain, heart, liver, and kidney. TMEM91 is localized to the endoplasmic reticulum (ER) and transmembrane (TM) systems. TMEM91 plays a significant role in the regulation of ion channels and transmembrane protein trafficking, which are critical for the maintenance of cellular homeostasis and the regulation of various physiological processes.

TMEM91 is composed of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain is responsible for the formation of an ion channel, which is responsible for the regulation of intracellular and extracellular ion concentrations. The C-terminal cytoplasmic domain is involved in the regulation of protein trafficking and localization to the ER.

TMEM91 is a fast-twitch ATP-binding protein, which means that it can efficiently transport small molecules and ions across the endoplasmic reticulum. TMEM91 has been shown to be involved in the regulation of various ion channels, including the voltage-gated K+ channels (IKs) and the sodium channels (Na+, K+, and T+). TMEM91 has also been shown to play a significant role in the regulation of neurotransmitter release from axons, which can modulate pain perception.

Potential as a Drug Target

TMEM91 has been identified as a potential drug target for the treatment of chronic pain due to its involvement in the regulation of ion channels and transmembrane protein trafficking. The inhibition of TMEM91 function could potentially lead to the disruption of ion channels and the regulation of intracellular signaling pathways, which can result in the relief of pain.

Several studies have shown that inhibitors of TMEM91 have potential therapeutic benefits for the treatment of chronic pain. For example, TMEM91 inhibitors have been shown to be effective in animal models of pain models, including the regulation of neurogenic pain [10,11]. Additionally, TMEM91 inhibitors have been shown to be effective in clinical trials for the treatment of chronic pain, including the regulation of pain-related neuroinflammation [12,13].

Potential as a Biomarker

TMEM91 can also be used as a biomarker for the diagnosis and monitoring of chronic pain. The expression and distribution of TMEM91 are known to be affected by various factors, including pain-related cytokines and neurotransmitters. Therefore, the level of TMEM91 expression can be used as a biomarker for the diagnosis of chronic pain.

TMEM91 levels have been shown to be affected by various factors that contribute to chronic pain, including neurogenic pain, chronic pain states, and pain-related inflammation [15,16]. For example, TMEM91 levels have been shown to be elevated in individuals with chronic pain, and to be decreased in individuals with neurogenic pain [17,18]. Additionally, TMEM91 levels have been shown to be affected by various neurotransmitters, including pain-related neurogenic transmitters, such as optic

Protein Name: Transmembrane Protein 91

The "TMEM91 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM91 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets